Two posters of the FACEHBI study will be presented to the eighth Conference Clinical Trials on Alzheimer's Disease in November
Fundació ACE will present two posters of the "Fundació ACE Healthy Brain Initiative" study. In both of them have participated researchers from Fundació ACE, the Hospital Clínic and the Clínica Corachan from Barcelona.
The first is titled "FACEHBI: a longitudinal study of Biomarkers and cognition in individuals with subjective cognitive decline." It is a study to determine whether cognitive decline is related to the presence of high levels of the protein amyloid in the brain.
To carry it out investigators have examined two hundred people selected following a list of requirements. From the one about the age of participants -49 years old or more- to the one about their clinical history -not having dementia or epilepsy diagnosed-.
Among the findings, we can highlight the claim that subjective cognitive impairment can be understood as an opportunity to identify people at high risk of cognitive impairment.
The second study is "White matter microstructure disruption is correlated with amyloid burden in subjects with subjective cognitive decline." The selection of participants for this one is similar to the first but this time it is found that the burden of amyloid is related to the deterioration of the tracts that connect the two cerebral hemispheres. This could be an early phenomenon in the pathophysiology of Alzheimer's disease.
ACE researchers who have participated in these studies:
Octavio Rodríguez-Gómez MD, Ángela Sanabria MS, Alba Pérez-Cordón MS, Susana Ruiz, Marina Tarragona, Domingo Sánchez-Ruíz MD, Sonia Moreno-Grau MS, Montserrat Alegret PhD, Ana Espinosa MS, Gemma Ortega PhD, Carla Abdelnour MD, Maiteé Rosende-Roca MD, Ana Mauleón MD, Liliana Vargas MD, Elvira Martín MSc, Sergi Valero PhD, Oscar Sotolongo-Grau PhD, Agustín Ruiz MD PhD, Isabel Hernández MD PhD, Lluís Tárraga MS, Mercè Boada MD PhD.